Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 4/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 5/20 | 0.32 |
| ▸ | JAK1 | P23458 | 5/20 | 0.32 |
| ▸ | JAK3 | P52333 | 5/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457706 | 0.79 | HTR6 (0.41) | L3MBTL1EPHX1XDHJAK2JAK1 | |
| SCHEMBL30682458 | 0.74 | L3MBTL1 (0.51) | L3MBTL1EPHX1PDE10AMEN1KMT2A | |
| SCHEMBL1228708 | 0.74 | L3MBTL1 (0.51) | L3MBTL1EPHX1PDE10AMEN1KMT2A | |
| SCHEMBL11942318 | 0.73 | L3MBTL1 (0.47) | L3MBTL1EPHX1PDE10AMEN1KMT2A | |
| SCHEMBL11952570 | 0.73 | L3MBTL1 (0.47) | L3MBTL1EPHX1PDE10AMEN1KMT2A | |
| SCHEMBL29169600 | 0.72 | L3MBTL1 (0.46) | L3MBTL1EPHX1PDE10AMEN1KMT2A | |
| SCHEMBL30682464 | 0.70 | SLC7A5 (0.43) | L3MBTL1EPHX1PDE10AMEN1KMT2A | |
| SCHEMBL2461789 | 0.69 | MPO (0.48) | L3MBTL1KMT2A | |
| SCHEMBL23300758 | 0.68 | L3MBTL1 (0.42) | L3MBTL1EPHX1MEN1KMT2A | |
| SCHEMBL29443974 | 0.66 | MEN1 (0.41) | L3MBTL1EPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010535-B1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | disclosed |
| US-8026244-B2 | Thioxanthine derivatives and their use as inhibitors of MPO | ASTRAZENECA AB (SE) | 2011-09-27 | — | — | US | disclosed |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| EP-2010535-A1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120098-A1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | MPO, XDH, EPX | L3MBTL1 1637/4885EPHX1 158/4885AURKA 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.